Published in PLoS One on February 17, 2012
Potential Cost-Effectiveness of Prenatal Distribution of Misoprostol for Prevention of Postpartum Hemorrhage in Uganda. PLoS One (2015) 1.38
Cost-Effectiveness in Global Surgery: Pearls, Pitfalls, and a Checklist. World J Surg (2017) 0.91
The influence of socioeconomic status on women's preferences for modern contraceptive providers in Nigeria: a multilevel choice modeling. Patient Prefer Adherence (2013) 0.84
Economic Evaluation of Family Planning Interventions in Low and Middle Income Countries; A Systematic Review. PLoS One (2016) 0.78
Health-related quality of life and social support among women treated for abortion complications in western Uganda. Health Qual Life Outcomes (2013) 0.78
"I Spent a Full Month Bleeding, I Thought I Was Going to Die…" A Qualitative Study of Experiences of Women Using Modern Contraception in Wakiso District, Uganda. PLoS One (2015) 0.75
Reducing unintended pregnancies: a microsimulation of contraceptive switching, discontinuation, and failure patterns in france. Stud Fam Plann (2014) 0.75
Factors influencing use of long-acting versus short-acting contraceptive methods among reproductive-age women in a resource-limited setting. BMC Womens Health (2017) 0.75
Stillbirth rates: delivering estimates in 190 countries. Lancet (2006) 5.70
Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med (2006) 5.62
Effectiveness and costs of interventions to lower systolic blood pressure and cholesterol: a global and regional analysis on reduction of cardiovascular-disease risk. Lancet (2003) 5.17
Handling uncertainty in cost-effectiveness models. Pharmacoeconomics (2000) 3.37
The incidence of induced abortion in Uganda. Int Fam Plan Perspect (2005) 2.02
The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health Econ Health Policy (2009) 1.94
Cost-effectiveness of traffic enforcement: case study from Uganda. Inj Prev (2008) 1.90
Costs of maternal health care services in three anglophone African countries. Int J Health Plann Manage (2003) 1.77
Patterns and trends in adolescents' contraceptive use and discontinuation in developing countries and comparisons with adult women. Int Perspect Sex Reprod Health (2009) 1.76
Collecting data on pregnancy loss: a review of evidence from the World Fertility Survey. Stud Fam Plann (1989) 1.21
Benefits of meeting the contraceptive needs of Ugandan women. Issues Brief (Alan Guttmacher Inst) (2009) 1.14
Estimating the costs of induced abortion in Uganda: a model-based analysis. BMC Public Health (2011) 1.13
Contraceptive efficacy of lactational amenorrhoea. Lancet (1992) 1.05
Abortion and maternal mortality in the developing world. J Obstet Gynaecol Can (2006) 1.01
Understanding contraceptive failure. Best Pract Res Clin Obstet Gynaecol (2009) 0.96
Cost effectiveness of facility-based care, home-based care and mobile clinics for provision of antiretroviral therapy in Uganda. Pharmacoeconomics (2009) 0.94
Benefits of meeting the contraceptive needs of Ethiopian women. Issues Brief (Alan Guttmacher Inst) (2010) 0.91
Maternal morbidity in developing countries: a review and comments. Int J Gynaecol Obstet (1992) 0.89
Assessing the cost-effectiveness of measles elimination in Uganda: local impact of a global eradication program. J Infect Dis (2011) 0.89
Vitamin A fortification in Uganda: comparing the feasibility, coverage, costs, and cost-effectiveness of fortifying vegetable oil and sugar. Food Nutr Bull (2010) 0.83
Cost-effectiveness of group psychotherapy for depression in Uganda. J Ment Health Policy Econ (2008) 0.81
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation (2008) 3.43
Pharmacovigilance activities in 55 low- and middle-income countries: a questionnaire-based analysis. Drug Saf (2010) 2.77
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med (2002) 2.43
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health (2008) 2.31
Genital ulcer disease treatment policies and access to acyclovir in eight sub-Saharan African countries. Sex Transm Dis (2010) 2.23
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy (2014) 2.02
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res (2012) 1.91
A validation study of patient interview data and pharmacy records for antihypertensive, statin, and antidepressant medication use among older women. Am J Epidemiol (2004) 1.85
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (2010) 1.83
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. BMC Health Serv Res (2009) 1.82
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost (2008) 1.76
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision. Ann Surg (2011) 1.63
Improving pediatric asthma outcomes in the community setting: does pharmaceutical care make a difference? J Am Pharm Assoc (Wash) (2002) 1.59
A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med (2012) 1.58
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol (2007) 1.58
Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics (2010) 1.55
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics. Genet Med (2012) 1.52
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Acad Radiol (2011) 1.45
The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg (2004) 1.45
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genomics (2006) 1.44
Optimizing CAD diagnosis in China with CT angiography. J Cardiovasc Comput Tomogr (2009) 1.43
Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state. Surg Obes Relat Dis (2012) 1.42
Neuroleptic drug exposure and incidence of tardive dyskinesia: a records-based case-control study. J Manag Care Pharm (2003) 1.40
Promoting the proper disposal of unused, unwanted, or expired medications. J Am Pharm Assoc (2003) (2014) 1.39
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. BMC Bioinformatics (2010) 1.32
The association between 3-hydroxy-3-methylglutaryl conenzyme A inhibitor use and breast carcinoma risk among postmenopausal women: a case-control study. Cancer (2004) 1.31
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med (2005) 1.27
Patient volume, human resource levels, and attrition from HIV treatment programs in central Mozambique. J Acquir Immune Defic Syndr (2011) 1.27
Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf (2007) 1.27
Determinants of use of intermittent preventive treatment of malaria in pregnancy: Jinja, Uganda. PLoS One (2010) 1.23
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Public health emergency preparedness and response communications with health care providers: a literature review. BMC Public Health (2011) 1.21
Global eradication of measles: an epidemiologic and economic evaluation. J Infect Dis (2011) 1.19
Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics (2010) 1.19
The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med (2004) 1.19
Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS One (2011) 1.19
A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. J Am Coll Surg (2003) 1.18
Prioritization in comparative effectiveness research: the CANCERGEN Experience. Med Care (2012) 1.17
Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med (2013) 1.16
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
Uterine rupture in a teaching hospital in Mbarara, western Uganda, unmatched case- control study. Reprod Health (2013) 1.14
Strengthening pharmaceutical care education in Ethiopia through instructional collaboration. Am J Pharm Educ (2011) 1.14
Estimating the costs of induced abortion in Uganda: a model-based analysis. BMC Public Health (2011) 1.13
An assessment of the accuracy and availability of data in electronic patient tracking systems for patients receiving HIV treatment in central Mozambique. BMC Health Serv Res (2012) 1.12
Determinants of use of insecticide treated nets for the prevention of malaria in pregnancy: Jinja, Uganda. PLoS One (2012) 1.12
Increasing incidence of serious hypoglycemia in insulin users. J Clin Epidemiol (2002) 1.12
Economic analyses of human genetics services: a systematic review. Genet Med (2005) 1.10
A review of selected patient-generated outcome measures and their application in clinical trials. Value Health (2003) 1.07
Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc (2003) 1.07
Estimating the effect of changes in body mass index on health state preferences. Pharmacoeconomics (2002) 1.06
Pregnancy exposure registries for assessing antimalarial drug safety in pregnancy in malaria-endemic countries. PLoS Med (2008) 1.06
Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer (2008) 1.06
Impact of mailed warning to prescribers on the co-prescription of tramadol and antidepressants. Pharmacoepidemiol Drug Saf (2005) 1.03
Implications of Part D for mentally ill dual eligibles: a challenge for Medicare. Health Aff (Millwood) (2006) 1.02
The ISPOR Good Practice Modeling Principles--a sensible approach: be transparent, be reasonable. Value Health (2003) 1.01
Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UK. Pharmacoeconomics (2006) 0.99
Epidemiology competency development and application to training for local and regional public health practitioners. Public Health Rep (2008) 0.99
Stakeholder perspectives on a risk-benefit framework for genetic testing. Public Health Genomics (2010) 0.98
Which antimicrobial impregnated central venous catheter should we use? Modeling the costs and outcomes of antimicrobial catheter use. Am J Infect Control (2003) 0.97
Patterns of anti-malarial drug treatment among pregnant women in Uganda. Malar J (2011) 0.97
Weight-related quality of life, health utility, psychological well-being, and satisfaction with exenatide once weekly compared with sitagliptin or pioglitazone after 26 weeks of treatment. Diabetes Care (2011) 0.97
The economics of genomic medicine: insights from the IOM Roundtable on Translating Genomic-Based Research for Health. JAMA (2013) 0.97
The value of comparative effectiveness research: projected return on investment of the RxPONDER trial (SWOG S1007). Contemp Clin Trials (2012) 0.97
Managed care in the genomics era: assessing the cost effectiveness of genetic tests. Am J Manag Care (2003) 0.96
Expectations, validity, and reality in pharmacogenetics. J Clin Epidemiol (2009) 0.96
Global pharmacovigilance for antiretroviral drugs: overcoming contrasting priorities. PLoS Med (2011) 0.96
Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res (2013) 0.96
Use of maximal sterile barriers during central venous catheter insertion: clinical and economic outcomes. Clin Infect Dis (2004) 0.95
Navigational bronchoscopy with biopsy versus computed tomography-guided biopsy for the diagnosis of a solitary pulmonary nodule: a cost-consequences analysis. J Bronchology Interv Pulmonol (2012) 0.95
An evaluation of the potential cost-effectiveness of non-invasive testing strategies in the diagnosis of significant liver fibrosis. J Gastroenterol Hepatol (2009) 0.95
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics (2005) 0.95
Pandemic policy and planning considerations for universities: findings from a tabletop exercise. Biosecur Bioterror (2007) 0.93
Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol (2004) 0.93
A review of public policy issues in promoting the development and commercialization of pharmacogenomic applications: challenges and implications. Drug Metab Rev (2008) 0.93